(Date:11/27/2009)...nprecedented medical, economic burdens, study pred...) -- The number of people with diabetes in the Uni...years, a new study predicts. , That would bring...th the disease, up from 23.7 million today. , , ... diabetes will triple, the study also warns, risin...
(Date:11/27/2009)... Voyant Health™ announced today that Spectr...s TraumaCad Enterprise orthopedic templating solut... (PRWEB) November 27, 2009...trum Health (Grand Rapids, Michigan) has licensed ...ution and its TraumaCad Extend workflow solution, ...
(Date:11/27/2009)... Specialist manufacturers who use medical load ce...ions of dollars by bringing in technology partner ...mbers of pro-active medical manufacturers are call...age of their projects, ensuring that progress will...r potentially outdated technology. , ...
(Date:11/26/2009)...RNewswire/--Withcoldandfluseasonuponus,it,smoreimp...eadofinfectionsandavoidillness. ,, "Weneedtobep...ansmittingillnessifwe,resick,"saidEileenFinerty,RN...torforinfectioncontrolandoccupationalhealthatHospi...alforSpecialSurgeryhasoneofthelowestinfectionrates...
(Date:11/26/2009)...the number of Americans living with diabetes will ...9 to 44.1 million in 2034. Over the same period, s...m $113 billion to $336 billion, even with no incre...d at the University of Chicago report in the Decem...ose with diabetes covered by Medicare will rise fr...
Breaking Medicine News(10 mins):Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Assetrac Location & Protection System
...-based and RFID-enabled location system that allow...nd utilization of resources throughout the periope...Trac collects patient information including locati...ht experience. This information is directed to bot...
RoamAlert Eco
awarix Enterprise Visibility Solutions for Healthcare
Medicine Products:
(Date:11/25/2009)...portlinker.comannouncesthatanewmarketresearchrepor...-GlobalTrends ,, http://www.reportlinker.com..., Widespreadavailabilityofgenericdrugs,emergence...acceleratedthepaceofgrowthinthepainmanagementmarke...uetoshapedemandforservices,drugsanddevices.Themark...
(Date:11/25/2009)...ewswire/-- ChemoCentryx,Inc.,announcedtodaythatPh...ProspectiveRandomizedOralTherapyEvaluationinCrohn,...swithmoderate-to-severeCrohn,sdiseasedemonstratedc...profile.Thestudydemonstratedevidenceofclinicaleffi...pointdecreaseintheCrohn,sDiseaseActivityIndex(CDAI...
(Date:11/24/2009)...-FirstCall/--QuestDiagnosticsIncorporated(NYSE: DG...nformationandservices,announcedthatitisscheduledto...ceinNewYorkCity.ThepresentationisscheduledforWedne...ringtheconference,thecompanywillreaffirmits2009gui...metoexceed18%ofrevenues,anddilutedearningspershare...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2New essays examine the use of fMRI to recognize deceit 48204 1New essays examine the use of fMRI to recognize deceit 48204 2Horse whisperers lion tamers not needed 3A Scientists find genetic regions that soothe savage beasts 8749 1Horse whisperers lion tamers not needed 3A Scientists find genetic regions that soothe savage beasts 8749 2HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University 12526 1HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University 12526 2HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University 12526 3...07-AstraZeneca today announced clinical,trial data...apine,fumarate sustained release), at the European...demonstrated that the SEROQUEL®,sustained rele...ease), administered once daily, significantly impr...red by PANSS) and increased the,time to psychiatri...
... 2007 /PRNewswire-FirstCall/ -- La Jolla,Pharmaceu...body,reduction data for the Phase 3 trial of Rique...stemic lupus erythematosus,("lupus" or "SLE"). The...n that there is a definitive and significant dose ...es of Riquent compared,with placebo (p=0.0001). Th...
Other Medicine Technology:Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 2Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 3Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6